# Novo Nordisk a S: overview NVO · NYSE · CIK 353278 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/nvo.md) · [Financials](/companies/nvo/financials.md) · [Filings](/companies/nvo/filings.md) · [Insiders](/companies/nvo/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $bn | [141](/filings/0001628280-24-002635.md) | [177](/filings/0001628280-25-003920.md) | [232](/filings/0000353278-26-000012.md) | [290](/filings/0000353278-26-000012.md) | [309](/filings/0000353278-26-000012.md) | | Gross margin | % | [83.2%](/filings/0001628280-24-002635.md) | [83.9%](/filings/0001628280-25-003920.md) | [84.6%](/filings/0000353278-26-000012.md) | [84.7%](/filings/0000353278-26-000012.md) | [81.0%](/filings/0000353278-26-000012.md) | | Operating margin | % | [41.7%](/filings/0001628280-24-002635.md) | [42.3%](/filings/0001628280-25-003920.md) | [44.2%](/filings/0000353278-26-000012.md) | [44.2%](/filings/0000353278-26-000012.md) | [41.3%](/filings/0000353278-26-000012.md) | | Net margin | % | [33.9%](/filings/0001628280-24-002635.md) | [31.4%](/filings/0001628280-25-003920.md) | [36.0%](/filings/0000353278-26-000012.md) | [34.8%](/filings/0000353278-26-000012.md) | [33.1%](/filings/0000353278-26-000012.md) | | Diluted EPS | $ per share | [10.37](/filings/0001628280-24-002635.md) | [12.22](/filings/0001628280-25-003920.md) | [18.62](/filings/0000353278-26-000012.md) | [22.63](/filings/0000353278-26-000012.md) | [23.03](/filings/0000353278-26-000012.md) | | Free cash flow | $bn | [48.7](/filings/0001628280-24-002635.md) | [66.7](/filings/0001628280-25-003920.md) | [83.1](/filings/0000353278-26-000012.md) | [73.8](/filings/0000353278-26-000012.md) | [59.0](/filings/0000353278-26-000012.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nvo/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Dodge & Cox](/funds/200217.md) | 2026-06-30 | $977.8m | 20,397,110 | | Added +1,063,360 | | [LOOMIS SAYLES & CO L P](/funds/312348.md) | 2026-06-30 | $891.4m | 18,594,352 | | Added +1,577,037 | | [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $625.2m | 13,041,109 | | Reduced −3,042,370 | | [PeakShares LLC](/funds/2113507.md) | 2026-06-30 | $606.1m | 12,642 | | Unchanged | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $575.7m | 12,009,200 | Call | Added +7,410,300 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $559.0m | 11,659,869 | | Added +790,669 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $535.8m | 11,176,712 | | Added +407,013 | | [Capital International Investors](/funds/1562230.md) | 2026-06-30 | $467.6m | 9,721,180 | | Reduced −2,074,670 | | [FOLKETRYGDFONDET](/funds/1269094.md) | 2026-06-30 | $456.5m | 9,522,383 | | Added +441,563 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $440.1m | 9,180,490 | | Added +4,059,453 | ## Recent filings [All 1,668 filings](/companies/nvo/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 12:33 ET | [6-K](/filings/0001171843-26-006813.md) | Report of a foreign private issuer, period 2026-10-26 | 0001171843-26-006813 | | 2026-10-19 | 08:31 ET | [6-K](/filings/0001171843-26-006685.md) | Report of a foreign private issuer, period 2026-10-19 | 0001171843-26-006685 | | 2026-10-13 | 06:15 ET | [6-K](/filings/0001171843-26-006585.md) | Report of a foreign private issuer, period 2023-10-12 | 0001171843-26-006585 | | 2026-10-06 | 08:11 ET | [6-K](/filings/0001171843-26-006440.md) | Report of a foreign private issuer, period 2026-10-05 | 0001171843-26-006440 | | 2026-10-05 | 17:53 ET | [6-K](/filings/0001171843-26-006374.md) | Report of a foreign private issuer, period 2026-10-02 | 0001171843-26-006374 | | 2026-09-28 | 11:23 ET | [6-K](/filings/0001171843-26-006248.md) | Report of a foreign private issuer, period 2026-09-28 | 0001171843-26-006248 | | 2026-09-21 | 11:11 ET | [6-K](/filings/0001171843-26-006128.md) | Report of a foreign private issuer, period 2026-09-21 | 0001171843-26-006128 | | 2026-09-17 | 12:21 ET | [6-K](/filings/0001171843-26-006088.md) | Report of a foreign private issuer, period 2026-09-17 | 0001171843-26-006088 | | 2026-09-15 | 06:00 ET | [6-K](/filings/0001171843-26-006038.md) | Report of a foreign private issuer, period 2026-09-14 | 0001171843-26-006038 | | 2026-09-09 | 06:00 ET | [6-K](/filings/0001171843-26-005925.md) | Report of a foreign private issuer, period 2026-09-07 | 0001171843-26-005925 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0000353278-26-000012.md), filed Feb 4, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 353278 - Tickers: NVO, NONOF - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: not reported - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 12:35 ET. No prices; not investment advice.